Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bromelain topical - MediWound

Drug Profile

Bromelain topical - MediWound

Alternative Names: anacaulase-bcdb; Debrase; Debrase Gel Dressing; KMW-1; NexoBrid; NexoBridN

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediWound
  • Developer Kaken Pharmaceutical; MediWound; Teva Pharmaceutical Industries; Tuteur
  • Class Anti-inflammatories; Cysteine endopeptidases; Skin disorder therapies
  • Mechanism of Action Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity No

Highest Development Phases

  • Marketed Burns
  • No development reported Wounds

Most Recent Events

  • 21 Mar 2024 MediWound anticipates approval of sBLA from the US FDA for Burns (In adolescents, In children, In infants, In neonates), in the second half of 2024
  • 10 Jan 2024 Preregistration for Burns (In adolescents, In children, In infants, In neonates) in USA (Topical)
  • 09 Jan 2024 Launched for Burns (In adolescents, In children, In infants, In neonates) in European Union (Topical), before January 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top